The components of successful vaccine development Treatments save patients, vaccines save populations Scientific Successful Compound Institutions Vaccine platform or Phase components execution of studies delivery mechanism • Correct target • Sufficiently large AZD1222 Univ. Oxford & AZ Adenovirus vaccine 2b/3 • Successful and long-term event rate Ad5-nCoV CanSinoBiologics Adenovirus vaccine 2 generation of protective • Sufficiently long mRNA-1273 Moderna mRNA vaccine 2 immunity enough duration Beijing Institute of Unnamed Biological Products & Inactivated vaccine 1/2 Sinopharm Distribution Manufacturing BNT162 BioNTech & Pfizer mRNA vaccine 1/2 capability capacity NVX- Novavax Protein subunit 1/2 • Prioritization and • Rapid scaling up CoV2373 coordination • Public-private PiCoVacc Sinovac Inactivated virus with 1/2 • “Last mile” efforts partnerships adjuvant Beth Israel Unnamed Deaconness& Adenovirus vaccine Janssen Source: Lancet 2020;395:1751-1752 and IQVIA insight. IQVIA Global Executive Briefing: COVID-19 June 2020; Copyright 2020 IQVIA. 11